Personalized Medicine: Histone biomarkers with PrognosDX
Submitted by Theral Timpson on Thu, 09/08/2011 - 10:45Guest:
Kamran Tahamtanzadeh, CEO, PrognosDX, Bio and Contact Info
Listen (8:13) Macro environment very important
<img src="/images/speaker.jpg" alt="Not just about a few markers/> Listen (2:27) Not just about a few markers
Listen (5:25) What does the service tell a doctor?
Listen (7:56) Histones studied only recently?
Listen (3:25) From scientist to businessman
Listen (2:03) Poet and painter
Listen (3:44) Histone like a soccer ball
Today we bring you the story of a company which is moving us closer to the promise of personalized medicine. Joining me is Kamran Tahamtanzadeh. He’s the founder and CEO of PrognosDX, a new company in Palo Alto, CA aiming to improve the treatment of cancer through epigenetic technology, specifically with histone biomarkers. Kamran was formerly with Ventana Medical Systems (now Roche) and MetriGenix.
